Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658485 | 0.92 | MAPT (0.40) | MAPTGPR119USP2SMN1; SMN2POLB | |
| SCHEMBL31079909 | 0.90 | MAPT (0.48) | MAPTGPR119USP2SMN1; SMN2POLB | |
| SCHEMBL14659735 | 0.90 | ESR2 (0.46) | MAPTGPR119POLBESR2NR1H2 | |
| SCHEMBL14659736 | 0.85 | PDK2 (0.42) | MAPTGPR119ESR2NR1H2GRM5 | |
| SCHEMBL19163908 | 0.84 | BUB1 (0.37) | MAPTGPR119POLBESR2NR1H2 | |
| SCHEMBL1992279 | 0.80 | MAPT (0.48) | MAPTGPR119POLBESR2NR1H2 | |
| SCHEMBL1996747 | 0.77 | ESR2 (0.46) | MAPTGPR119ESR2NR1H2GRM5 | |
| SCHEMBL10687396 | 0.77 | BUB1 (0.34) | MAPTGPR119POLBESR2NR1H2 | |
| SCHEMBL22650893 | 0.76 | MAPT (0.46) | MAPTGPR119ESR2NR1H2GRM5 | |
| SCHEMBL28948295 | 0.76 | ESR2 (0.45) | MAPTESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2736907-B1 | INDAZOLES | PFIZER LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-8895544-B2 | Indazoles | PFIZER LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| EP-2736907-A1 | INDAZOLES | Pfizer Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20140024634-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| US-8575336-B2 | Indazoles | PFIZER LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-20130029968-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014567-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029968-A1 | INDAZOLES | CYP11B2, CYP11B1, IL33 | MAPT 1270/4885GPR119 395/4885USP2 4137/4885 |
| US-20140024634-A1 | INDAZOLES | JAK1, JAK3, JAK2 | MAPT 515/4885GPR119 1640/4885USP2 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.